Acyclovir in the management of herpes virus infections in immunosuppressed children.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to I B Hillary.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The results of a randomised double-blind clinical trial of 3% acyclovir and 0.5% idoxuridine (IDU) ophthalmic ointments in 60 patients with corneal dendritic ulceration are presented. Ulcers in all 30 patients treated with acyclovir healed compared with 22 (76%) of 29 patients treated with IDU (P < 0.01). Patients treated with acyclovir healed more rapidly (average 4.4 days) than those who received IDU (average 9.2 days) (P < 0.01). No serious side effects were observed, though transient stinging was recorded in 8 patients receiving acyclovir and in 2 patients receiving IDU. Other side effects in the IDU treated group were watering in 2 patients and superficial punctate erosions in 6 patients.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A total of 21 rubella seronegative children vaccinated subcutaneously with Wistar RA 27/3 strain live attenuated rubella vaccine in a family study of vaccine virus transmissibility were reviewed after 6 years. Haemagglutinating inhibiting (HAI) antibody titres of sera collected 46 days, 2 years and 6 years after vaccination were compared. Antibody titres in the vaccinated subjects were not significantly influenced by time, infection in susceptible siblings or revaccination.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
After subcutaneous vaccination of rubella sero-negative children with Wistar RA 27/3 rubella vaccine, haemagglutination-inhibiting antibody titres were compared in sera taken 46 days and 2 years after vaccination. Antibody titres were well maintained in the absence of any known exposure to natural infection.
No evidence of vaccine virus transmission was found in two studies where Wistar RA 27/3 rubella vaccine was administered intranasally. Vaccine was immunogenic in all of 23 vaccinated children in one study, while in the other only 5 of the 11 vaccinees developed antibody. The reduced seroconversion rate in the latter study appears to have been caused by one or a combination of factors, including the vaccination technique, the presence of infective nasal conditions in vaccinees and the titre of vaccine used.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A study with RA 27/3 attenuated rubella virus vaccine (Plotkin strain) showed that this produced a significant antibody response in all of twenty-one vaccinated non-immune children without any appreciable marked clinical reactions. Serological examination of 53 non-immune and 29 immune siblings living in the same households failed to show any evidence of transmission of infection.